Jazz Pharmaceuticals received a boost from positive topline data from a late-stage study of Ziihera in gastro-esophageal adenocarcinoma, which uplifts the company's oncology revenue outlook but is...
Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says